Botulinum Toxin (Botox and Its Approved Siblings)

Botulinum toxin type A is a real, decades-approved protein drug — first cleared by the FDA in 1989 and now marketed as five separate branded products, with genuine trial evidence behind more than a dozen indications. It's also, unusually for this site, a drug whose grey-market risk shows up not as a research-chemical sales pitch but as two real, CDC-documented outbreaks of unlicensed and counterfeit injections and, more recently, people self-injecting product bought online.

What it is, and how it works

Botulinum toxin is a large (roughly 150 kDa) protein neurotoxin produced by the bacterium Clostridium botulinum — the same toxin responsible for botulism, a rare but serious paralytic illness. It works by entering nerve endings and cleaving SNARE proteins required for the release of acetylcholine, the neurotransmitter that tells a muscle to contract or a gland to secrete. Injected at a tiny, precisely measured dose directly into a specific muscle or gland, that same mechanism produces a controlled, local, temporary reduction in muscle activity or sweat gland output — lasting roughly three to four months before nerve signaling gradually returns, which is why treatment is repeated on a schedule rather than being a one-time fix.

The approval history: four decades, a dozen-plus indications

The FDA first cleared botulinum toxin type A for clinical use in December 1989, under the name Oculinum, for two eye-muscle conditions: strabismus and blepharospasm. Allergan had already acquired the rights to the product and renamed it Botox shortly afterward. From there, the approved indication list grew steadily and for years had nothing to do with cosmetics: cervical dystonia in 2000, severe primary axillary hyperhidrosis (excessive underarm sweating) in 2004, and upper-limb spasticity in 2010. The now-famous cosmetic approval — for temporarily improving moderate-to-severe glabellar lines, the vertical frown lines between the eyebrows — didn't arrive until 2002, thirteen years after the original approval. Chronic migraine prevention followed in October 2010, based on the PREEMPT program: two large placebo-controlled Phase 3 trials totaling 1,384 adults with chronic migraine (defined as headache on 15 or more days a month), across 122 sites in North America and Europe. Urinary incontinence from neurogenic detrusor overactivity (in patients with a neurological condition like multiple sclerosis or spinal cord injury) was added in August 2011, followed by a separate approval for idiopathic overactive bladder — unrelated to a neurological condition — in January 2013, based on two trials totaling over 1,100 patients. A 2009 FDA-mandated boxed warning, applied to all licensed botulinum toxin products, covers a genuine if rare risk: the toxin's effect spreading beyond the injection site to cause symptoms resembling botulism itself — swallowing and breathing difficulty that has, in isolated cases, been fatal — usually reported in patients treated for pediatric spasticity at doses well above cosmetic ones.

Five brands, one mechanism

Botox (onabotulinumtoxinA, AbbVie/Allergan) has company. Dysport (abobotulinumtoxinA, Ipsen) was approved on 29 April 2009 for cervical dystonia and glabellar lines simultaneously — one therapeutic indication and one cosmetic one in the same approval — later expanded to spasticity. Xeomin (incobotulinumtoxinA, Merz) followed in 2010; it's formulated without the accessory proteins the other products carry, marketed as a "naked" toxin, though no head-to-head trial on this site's radar has shown that difference to matter clinically. Jeuveau (prabotulinumtoxinA, Evolus) was approved in 2019 for cosmetic use only. Daxxify (daxibotulinumtoxinA, Revance) is the newest, approved in 2022 for glabellar lines and in 2023 for cervical dystonia, formulated with a peptide excipient the company markets as extending its effect duration. All five are the same class of drug — a purified botulinum toxin type A protein — differing in formulation, dosing units (which are not interchangeable between brands), and specific approved indications, not in fundamental mechanism.

The 2024 counterfeit-injection outbreak

The 2025 DIY self-injection cases

A newer and more directly relevant pattern surfaced in a November 2025 CDC report: during May-June 2025, three women (ages 29, 50 and 59) in New York, Texas and Wisconsin became severely ill after self-injecting botulinum toxin they had purchased online — reportedly from sellers in Korea and China — outside any clinical setting at all. One injected roughly 11 units into her eyebrows, forehead and lips, developing double vision, difficulty swallowing, a drooping eyelid and voice changes days later; another injected roughly 200 units into her neck and developed bilateral arm weakness, difficulty swallowing and shortness of breath within two days, requiring six days of hospitalization including invasive mechanical ventilation. All three were hospitalized, all three received botulinum antitoxin after their treating clinicians consulted with the CDC, and all recovered but with some residual signs and symptoms persisting (Notes from the Field, MMWR 2025;74(38):593-596). This is a distinct failure mode from the 2024 cases: not a counterfeit product administered by an unlicensed third party, but a person buying a product online — of unknown identity, concentration or sterility — and injecting it themselves, the same basic risk pattern this site's vendor-safety and RUO-labeling pages describe for injectable peptides generally. The CDC's explicit guidance in response: botulinum toxin should only be administered by a licensed, trained medical professional, using FDA-approved product obtained directly from the manufacturer or an authorized distributor — never self-injected, and never sourced online outside that supply chain.

Current status

All five branded botulinum toxin products remain FDA-approved and in wide, mainstream clinical and cosmetic use, prescribed and administered by licensed providers under cold-chain-controlled distribution. The 2024 and 2025 cases described above are not a finding against the approved drug's safety record when properly sourced and administered by a trained clinician — they are a documented pattern of the same drug being obtained outside that system entirely, whether through an unlicensed injector using counterfeit product or a buyer injecting themselves with product purchased online. That distinction — approved drug, controlled supply chain, licensed administration, versus everything outside that — is the same one this site draws for injectable peptides generally, and the CDC's own 2025 guidance draws it explicitly for botulinum toxin too.